文献速递脊柱关节炎

验证适用于脊柱关节炎的自我管理合并症问卷:ASAS-COMOSPA研究结果

Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本研究基于ASAS-COMOSPA研究数据,验证了改良自我管理合并症问卷(mSCQ)在脊柱关节炎(SpA)患者中的有效性,并评估添加关节外表现(EAMs)、骨质疏松和骨折条目后效度是否改善。结果显示mSCQ是评估合并症对健康结局影响的有效自评工具,但添加EAMs和/或骨质疏松或骨折并未提高其效度。

要点

  • mSCQ是评估SpA患者合并症影响的有效自评工具。
  • 患者自报与医生确认的EAMs一致性为中等至几乎完全(葡萄膜炎κ=0.81,IBD κ=0.73,银屑病κ=0.86)。
  • 添加EAMs、骨质疏松和/或骨折未改善mSCQ效度。

核心结论

  • mSCQ是评估SpA患者合并症对健康结局影响的有效自评工具。
  • 添加EAMs和/或骨质疏松或骨折并未提高mSCQ的效度。

研究设计与样本

  • 基于ASAS-COMOSPA研究数据,共纳入3984例患者进行分析。
  • 评估EAMs、骨质疏松和骨折存在的标准效度,采用患者自报与医生确认疾病之间的一致性(kappa)。
  • 通过检验mSCQ(含EAMs、骨质疏松和/或骨折,即SpA-SCQ)与人口学、身体功能、工作能力、健康效用和疾病活动的相关性假设来评估结构效度,并与风湿病合并症指数进行比较。

主要发现

  • 患者自报与医生报告的EAMs一致性为中等至几乎完全(葡萄膜炎κ=0.81,IBD κ=0.73,银屑病κ=0.86)。
  • 骨质疏松(κ=0.38)和骨折(κ=0.39)的一致性为一般。
  • mSCQ与年龄、身体功能、工作限制和健康效用呈中度至弱相关,与疾病活动呈极弱相关。
  • 与假设相反,添加EAMs、骨质疏松和/或骨折降低了mSCQ与多个外部构念的相关性,尤其是在外周型SpA患者中。
  • mSCQ和SpA-SCQ与不同构念的相关性均强于风湿病合并症指数(rBASFI=0.34;rEQ-5D=-0.33 vs rBASFI=0.24;rEQ-5D=-0.21)。

关键数值与推荐

  • EAMs一致性:葡萄膜炎κ=0.81,IBD κ=0.73,银屑病κ=0.86。
  • 骨质疏松κ=0.38,骨折κ=0.39。
  • mSCQ和SpA-SCQ与BASFI相关性r=0.34,与EQ-5D相关性r=-0.33;风湿病合并症指数与BASFI相关性r=0.24,与EQ-5D相关性r=-0.21。

临床怎么用

  • mSCQ可作为SpA患者合并症影响健康结局的有效自评工具。
  • 不建议在mSCQ中添加EAMs、骨质疏松或骨折条目以改善效度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To confirm validity of the Self-administered Comorbidity Questionnaire modified for patients with SpA (mSCQ), and assess whether validity improves when adding items on extra-articular manifestations (EAMs), i.e. uveitis, psoriasis, and IBD, and osteoporosis and fractures. METHODS: Data from the Assessment in SpondyloArthritis international Society COMOrbidities in SPondyloArthritis study were used. Criterion validity of presence of EAMs, osteoporosis and fractures was assessed as agreement (kappa) between patients' self-reported and physician-confirmed disease. Construct validity of the mSCQ including EAMs, osteoporosis and/or fractures (SpA-SCQ) was assessed by testing hypotheses about correlations with demographics, physical function, work ability, health utility and disease activity, and was compared with construct validity of the rheumatic disease comorbidity index. RESULTS: In total, 3984 patients contributed to the analyses. Agreement between patient-reported and physician-reported EAMs was substantial to almost perfect (uveitis ĸ = 0.81, IBD ĸ = 0.73, psoriasis ĸ = 0.86). Agreement for osteoporosis (ĸ = 0.38) and fractures (ĸ = 0.39) was fair. As hypothesized, the mSCQ correlated moderately to weakly with age, physical function, work limitations and health utility, and very weakly with disease activity. In contrast to our hypothesis, adding EAMs, osteoporosis and/or fractures to the mSCQ decreased correlations with several external constructs, especially among patients with peripheral SpA. Correlations with the different constructs were stronger for the both mSCQ and SpA-SCQ (rBASFI = 0.34; rEQ-5D = -0.33) compared with the rheumatic disease comorbidity index (rBASFI = 0.24; rEQ-5D = -0.21). CONCLUSION: The mSCQ is a valid self-report instrument to assess the influence of comorbidities on health outcomes in patients with SpA. Adding EAMs and/or osteoporosis or fractures does not improve validity of the mSCQ.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Stolwijk C, Essers I, van den Bosch F, et al. Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. Rheumatology (Oxford). 2020. PMID: 31665462. doi:10.1093/rheumatology/kez482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。